Christopher Pierce - 02 Sep 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: EVP and Chief of Business Oper
Signature: /s/ Brian Piper, Attorney-in-Fact
Issuer symbol: PRLD
Transactions as of: 02 Sep 2021
Net transactions value: -$490,043
Form type: 4
Filing time: 07 Sep 2021, 19:17:05 UTC
Previous filing: 22 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRLD	Common Stock	Options Exercise	$218,450	+17,000	+453%	$12.85	20,750	02 Sep 2021	Direct
transaction	PRLD	Common Stock	Sale	$134,697	-3,343	-16%	$40.29^*	17,407	02 Sep 2021	Direct	F1, F2
transaction	PRLD	Common Stock	Sale	$279,289	-6,727	-39%	$41.52^*	10,680	02 Sep 2021	Direct	F1, F3
transaction	PRLD	Common Stock	Sale	$294,507	-6,930	-65%	$42.50^*	3,750	02 Sep 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRLD	Employee Stock Option (right to buy)	Options Exercise	$0	-17,000	-7.6%	$0.000000	207,796	02 Sep 2021	Common Stock	17,000	$12.85	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F5	The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.